tailieunhanh - Effects of sitagliptin as add on blood glucose level in patients with type 2 diabetes in national hospital of endocrinology

To evaluate effects of dipeptidyl peptidase (DPP)-4 inbibitors sitagliptin as addon therapy on blood glucose in patients with type 2 diabetes inadequately controlled with oral antidiabetic drug (OAD) monotherapy or combination. | Journal of military pharmaco-medicine no4-2018 EFFECTS OF SITAGLIPTIN AS ADD-ON BLOOD GLUCOSE LEVEL IN PATIENTS WITH TYPE 2 DIABETES IN NATIONAL HOSPITAL OF ENDOCRINOLOGY Le Thi Viet Ha*; Doan Van De** SUMMARY Objectives: To evaluate effects of dipeptidyl peptidase (DPP)-4 inbibitors sitagliptin as addon therapy on blood glucose in patients with type 2 diabetes inadequately controlled with oral antidiabetic drug (OAD) monotherapy or combination. Subjects and methods: An interventional study was conducted on 101 adult patients with type 2 diabetes inadequately controlled with OAD monotherapy or combination other than DPP-4 inhibitors with HbA1c from 7 to 10%. The outcome measures were fasting plasma glucose (FPG), 2 hour postprandial glucose (2hPPG) and HbA1c that were assessed at the baseline, after 12 and 24 weeks. A DDP-4 inhibitor was started with a half or full dose for the first 12 weeks and increased to full dose for the last 12 weeks if started as half dose. The other OAD and their doses were kept unchanged during the whole study. Results: The mean age and diabetes duration was ± and ± years, respectively. Before the study, metformin monotherapy was used by of patients and the most used combination was metformin plus sulfonylurea ( mg in all the patients). Sitagliptin was the only used DPP-4 inhibitor with mean dose of mg/day and mg/day for the first and second 12 weeks. After 24 weeks, compared to the baseline, the mean FPG, 2hPPG and HbA1c significantly further decreased by mmol/L, mmol/L and , respectively (p Sitagliptin 100 mg/day [n (%)] 77 () 74 () > Mean ± SD (mg per day) ± ± > All the antidiabetic drug(s) used before the study and their doses remained unchanged during the whole study. All the patients received sitagliptin at a daily dose of 50 mg or 100 mg that was unchanged until week 12. For weeks 1 to 12, and of the patients .

TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.